AGP
VRTX icon

Autumn Glory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Autumn Glory Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-800
Closed -$326K – 177
2023
Q4 		$326K Hold
800
– – 0.19% 116
2023
Q3 		$278K Hold
800
– – 0.17% 118
2023
Q2 		$282K Hold
800
– – 0.21% 108
2023
Q1 		$252K Hold
800
– – 0.22% 106
2022
Q4 		$231K Hold
800
– – 0.12% 145
2022
Q3 		$232K Buy
+800
New +$230K 0.16% 130

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Autumn Glory Partners's VRTX Position: Q1 2024 in Review

Autumn Glory Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 800 shares — an estimated $326K sold.

Autumn Glory Partners first reported a position in VRTX in Q3 2022 and held it in 6 quarters. The position peaked at $326K in Q4 2023. 1,497 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Autumn Glory Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Autumn Glory Partners sold 800 Vertex Pharmaceuticals shares in Q1 2024, an estimated $326K.
  • Autumn Glory Partners first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Autumn Glory Partners's Vertex Pharmaceuticals position peaked at $326K in Q4 2023.
  • 1,497 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Autumn Glory Partners's 13F filing for Q1 2024, filed 30 Apr 2024.